A Randomized Phase II Trial of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced EGFR Wild-Type and EGFR FISH-Positive Lung Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2014
At a glance
- Drugs Erlotinib (Primary) ; Pemetrexed
- Indications Lung cancer
- Focus Therapeutic Use
- 20 Nov 2013 Actual initiation date changed from Apr 2012 to Dec 2008 as reported by ClinicalTrials.gov.
- 16 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 Apr 2012 New trial record